CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Influence of baseline HbA1c, BMI, β-cell function and insulin sensitivity on the treatment response of empagliflozin in patients with type 2 diabetes
DOI 10.1055/s-0036-1580784
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Ridderstrale, U Elsasser, C Zeller, S Hantel, A Salsali, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: Empagliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, inhibits renal glucose reabsorption, leading to glucosuria and improved fasting and postprandial glucose. Due to its renal mechanism of action, we hypothesized that glucose lowering with empagliflozin is independent of β-cell function and insulin resistance. Methods: Using pooled data from three 24-week trials that investigated e…
Zitieren
Zitierempfehlung
M Ridderstrale, U Elsasser, C Zeller, S Hantel, A Salsali, UC Broedl (2016) Influence of baseline HbA1c, BMI, β-cell function and insulin sensitivity on the treatment response of empagliflozin in patients with type 2 diabetes. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580784
Mit CareLit weiterarbeiten